About DIASTOL THERAPEUTICS, LLC
Diastol Therapeutics is an emerging biotechnology company focused on developing treatments for Heart Failure with Preserved Ejection Fraction (HFpEF), a condition with significant unmet clinical need. The company is based in Chicago, IL, and Minneapolis, MN, and was founded in 2018.
Development of first-in-class drug candidates for cardiovascular diseaseOngoing non-human primate studies and optimization of lead compound PD assays, CMC, and tox. studiesExploration of mitochondrial-targeted compounds, such as Mito-58, to improve mitochondrial functionScreening for additional compounds with mitochondrial-directed activity for portfolio expansionDevelopment of diagnostics and biomarkers alongside therapeutic programs
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to DIASTOL THERAPEUTICS, LLC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.